利奈唑胺联合利福平在小鼠MRSA肺炎模型中活性增强
在小鼠肺炎模型中比较利奈唑胺联合利福平对cfr阳性与cfr阴性临床MRSA菌株的疗效,联合用药使利奈唑胺MIC下降2至16倍,对全部cfr阳性菌株呈协同作用(FICI≤0.5),并显著改善疗效,联合治疗所需fAUC/MIC靶值较单药降低2.4至6.7倍(P<0.005)。
要点
- 利奈唑胺联合利福平使研究MRSA菌株对利奈唑胺的MIC下降2至16倍。
- 联合用药对全部cfr阳性MRSA分离株FICI≤0.5,呈协同活性。
- 联合治疗所需利奈唑胺fAUC/MIC靶值较单药降低2.4至6.7倍(P<0.005)。
核心结论
- 利奈唑胺联合利福平在cfr基因存在与缺失的MRSA菌株所致小鼠肺炎模型中均显著改善利奈唑胺疗效。
研究设计与样本
- 采用棋盘法和时间杀菌试验评价利奈唑胺与利福平的协同活性。
- 在小鼠肺炎模型中研究血浆和上皮衬液(ELF)的药代动力学及利奈唑胺单药与联合利福平的疗效。
- 采用Emax Hill方程拟合剂量-反应关系。
主要发现
- 联合利福平后研究MRSA菌株对利奈唑胺的MIC较利奈唑胺单药下降2至16倍。
- 联合用药对全部cfr阳性MRSA分离株的FICI≤0.5,呈协同活性。
- 利奈唑胺肺穿透良好,ELF/f血浆AUC比值为2.68±0.17。
- 在cfr阳性与cfr阴性MRSA菌株肺炎模型中,加用利福平均显著改善利奈唑胺疗效。
- 利奈唑胺在血浆中与抑菌、1 log10杀菌和2 log10杀菌相关的fAUC/MIC靶值分别为15.9、38.8和175,在ELF中分别为43.5、108和415。
关键数值与推荐
- 联合利福平后利奈唑胺MIC较单药下降2至16倍。
- 对全部cfr阳性MRSA分离株FICI≤0.5。
- ELF/f血浆AUC比值为2.68±0.17。
- 利奈唑胺fAUC/MIC靶值:血浆中抑菌15.9、1 log10杀菌38.8、2 log10杀菌175;ELF中抑菌43.5、1 log10杀菌108、2 log10杀菌415。
- 联合利福平治疗时利奈唑胺在血浆和ELF中的fAUC/MIC靶值较利奈唑胺单药低2.4至6.7倍(P<0.005)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The chloramphenicol/florfenicol resistance gene cfr, which mediates cross-resistance to linezolid and other classes of antimicrobial agents, represents a global therapeutic challenge due to its dissemination among MDR nosocomial pathogens, including MRSA. This study aimed to compare the efficacy of the linezolid/rifampicin combination in a murine pneumonia model caused by cfr-positive and cfr-negative clinical MRSA strains. METHODS: Synergistic activity between linezolid and rifampicin was evaluated by chequerboard and time-kill assays. Pharmacokinetic profiles in plasma and epithelial lining fluid (ELF) as well as the therapeutic efficacy of linezolid alone and in combination with rifampicin were investigated in a murine pneumonia model. The Emax Hill equation was used to model the dose-response relationship. RESULTS: Increased susceptibility of the study MRSA strains to linezolid was observed with the rifampicin combination (MIC decreased 2- to 16-fold versus linezolid alone). The combination had synergistic activity (fractional inhibitory concentration index ≤0.5) against all cfr-positive MRSA isolates. Linezolid demonstrated excellent pulmonary penetration with an ELF/fplasma AUC ratio of 2.68 ± 0.17. The addition of rifampicin significantly improved the efficacy of linezolid in the pneumonia model due to cfr-positive and cfr-negative MRSA strains. The fAUC/MIC targets of linezolid associated with stasis, 1 log10 kill and 2 log10 kill were 15.9, 38.8 and 175 in plasma, and 43.5, 108 and 415 in ELF, respectively. Importantly, the linezolid fAUC/MIC targets in both plasma and ELF were 2.4-6.7 times lower in combined linezolid/rifampicin therapy versus linezolid monotherapy (P < 0.005). CONCLUSIONS: Combination of linezolid with rifampicin significantly improved the efficacy of linezolid in the murine pneumonia model caused by MRSA strains in the presence and absence of the cfr gene.
引用
- Zhou YF, Xiong YQ, Tao MT, et al. Increased activity of linezolid in combination with rifampicin in a murine pneumonia model due to MRSA. J Antimicrob Chemother. 2018. PMID: 29897466. doi:10.1093/jac/dky129
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。